"Quote:
It’s officially been returned to RIGL:
finance.yahoo.com/news/Rigel-Assumes-Development-prnews-2774177046.html?x=0&.v=1
No impact at all on the stock. I thought it might dip at least a little bit on this ultimate news, notwithstanding the fact that fostamatinib is by far and away the biggest key to the RIGL story."
Well, it was 95% certain several months ago that this is what would happen, so for once it actually got baked in when the writing was on the wall instead when the news became confirmed. Was kind of hoping for a dip myself. I keep telling myself, this thing is a buy under 8 bucks, but I fail to actually buy. And watching while that becomes true. 4th mouse gets the cheese?
Regards, RockRat
Market Data 
Markets 
AI
